4.7 Article

Biological evaluation and molecular docking of baicalin and scutellarin as Helicobacter pylori urease inhibitors

期刊

JOURNAL OF ETHNOPHARMACOLOGY
卷 162, 期 -, 页码 69-78

出版社

ELSEVIER IRELAND LTD
DOI: 10.1016/j.jep.2014.12.041

关键词

Baicalin; Scutellarin; Helicobacter pylori; Urease; Non-competitive inhibitior; Molecular docking

资金

  1. National Natural Science Foundation of China [81374043]
  2. Specialized Research Fund for the Doctoral Program of Higher Education, Guangdong International Cooperation Project [2012B050300002]
  3. Special Funds from Central Finance of China in Support of the Development of Local Colleges and University, Educational finance Grant [276(2014)]
  4. Doctoral Fund of Ministry of Education of the People's Republic of China [20134425110009]
  5. College students' innovative & entrepreneurial training plan project of Guangdong province [1057213043]

向作者/读者索取更多资源

Ethnopharmacological relevance: Baicalin and scutellarin are the principal bioactive components of Scutellaria baicalensis Georgi which has extensively been incorporated into heat-clearing and detoxification formulas for the treatment of Helicobacter pylori-related gastrointestinal disorders in traditional Chinese medicine. However, the mechanism of action remained to be defined. Aim of the study: To explore the inhibitory effect, kinetics and mechanism of Helicobacter pylori urease (the vital pathogenetic factor for Helicobacter pylori infection) inhibition by baicalin and scutellarin, for their therapeutic potential. Materials and methods: The ammonia formations, indicator of urease activity, were examined using modified spectrophotometric Berthelot (phenol-hypochlorite) method. The inhibitory effect of baicalin and scutellarin was characterized with IC50 values, compared to acetohydroxamic acid (AHA), a well known Helicobacter pylori urease inhibitor. Lineweaver-Burk and Dixon plots for the Helicobacter pylori urease inhibition of baicalin and scutellarin was constructed from the kinetic data. SH-blocking reagents and competitive active site Ni2+ binding inhibitors were employed for mechanism study. Molecular docking technique was used to provide some information on binding conformations as well as confirm the inhibition mode. Moreover, cytotoxicity experiment using Gastric Epithelial Cells (GES-1) was evaluated. Results: Baicalin and scutellarin effectively suppressed Helicobacter pylori urease in dose-dependent and time-independent manner with IC50 of 0.82 +/- 0.07 mM and 0.47 +/- 0.04 mM, respectively, compared to AHA (IC50 = 0.14 +/- 0.05 mM). Structure-activity relationship disclosed 4'-hydroxyl gave flavones an advantage to binding with Helicobacter pylori urease. Kinetic analysis revealed that the types of inhibition were noncompetitive and reversible with inhibition constant K-i of 0.14 +/- 0.01 mM and 0.18 +/- 0.02 mM for baicalin and scutellarin, respectively. The mechanism of urease inhibition was considered to be blockage of the SH groups of Helicobacter pylori urease, since thiol reagents (L,D-dithiothreitol, L-cysteine and glutathione) abolished the inhibitory action and competitive active site Ni2+ binding inhibitors (boric acid and sodium fluoride) carried invalid effect Molecular docking study further supported the structure-activity analysis and indicated that baicalin and scutellarin interacted with the key residues Cys321 located on the mobile flap through S-H . pi interaction, but did not interact with active site Ni2+. Moreover, Baicalin (at 0.59-1.05 mM concentrations) and scutellarin (at 023-0.71 mM concentrations) did not exhibit significant cytotoxicity to GES-1. Conclusions: Baicalin and scutellarin were non-competitive inhibitors targeting sulfhydryl groups especially Cys321 around the active site of Helicobacter pylori urease, representing potential to be good candidate for future research as urease inhibitor for treatment of Helicobacter pylori infection. Furthermore, our work gave additional scientific support to the use of Scutellarki baicalensis in traditional Chinese medicine (TCM) to treat gastrointestinal disorders. (C) 2015 Elsevier Ireland Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据